Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an o...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ord, J J, Streeter, E, Jones, A, Le Monnier, K, Cranston, D, Crew, J, Joel, S P, Rogers, M A, Banks, R E, Roberts, I S D, Harris, A L
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2005
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361814/
https://ncbi.nlm.nih.gov/pubmed/15928663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602650
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg